WALTHAM, Mass., Sept. 25, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced the
appointment of Jennifer Jarrett and
William Meury to its Board of
Directors, effective today. Ms. Jarrett and Mr. Meury will
succeed Luke Evnin, Ph.D. and
Henry Chen, who resigned as active
members of the Syndax Board of Directors, effective today.
"It is a pleasure to welcome Jennifer and Bill, both highly
accomplished leaders in the biopharmaceutical industry, to our
Board of Directors," said Dennis
Podlesak, Chairman of Syndax. "Jennifer brings to the Board
a wealth of financial and operational expertise, with a proven
track record of creating and building value for numerous publicly
traded biotech companies. Bill's extensive experience successfully
launching and commercializing healthcare products will be
invaluable as we move closer to the potential commercialization of
entinostat. I look forward to their contributions and insights as
Syndax continues its efforts to advance its innovative pipeline of
cancer therapies and evolve into a commercial organization."
Mr. Podlesak added, "On behalf of the entire Board, I would like
to thank Luke and Henry for their dedication and commitment to
Syndax over the years. We wish them both the best of luck in all of
their future endeavors."
Ms. Jarrett currently serves as Chief Operating Officer and
Chief Financial Officer of Arcus Biosciences, a publicly traded
biotechnology company developing next generation cancer
immunotherapies. Prior to Arcus, Ms. Jarrett was Chief
Financial Officer of Medivation up until the company's sale to
Pfizer in 2016. Before Medivation, Ms. Jarrett spent 20 years
in investment banking, most recently at Citigroup where she was
responsible for the firm's West Coast life sciences investment
banking practice. Prior to Citigroup, Ms. Jarrett worked in the
investment banking divisions of Credit Suisse, Donaldson, Lufkin
& Jenrette, Merrill Lynch and Kidder
Peabody. Ms. Jarrett currently serves on the Board of
Directors of Arena Pharmaceuticals and Audentes Therapeutics. She
holds an M.B.A. from the Stanford Graduate School of Business and
earned her bachelor's degree in Economics from Dartmouth College.
Mr. Meury currently serves as the Chief Commercial Officer of
Allergan, plc, a global, publicly traded pharmaceutical company. He
began his tenure at Allergan in 2014 as Executive Vice President,
Commercial, North American Brands, and subsequently held the role
of President, Branded Pharma. Prior to joining Allergan, Mr. Meury
served as Executive Vice President, Sales and Marketing at Forest
Laboratories, Inc. prior to its acquisition by Allergan, then known
as Actavis. He joined Forest in 1993 and held multiple roles of
increasing responsibility in Marketing, New Products, Business
Development, and Sales. Before joining Forest, Mr. Meury worked in
public accounting for Reznick Fedder
& Silverman and in financial reporting for MCI Communications.
He is currently on the Board of Directors of several organizations,
including The Jed Foundation and International Council of
Ophthalmology Foundation. Mr. Meury earned his bachelor's degree in
Economics from the University of
Maryland.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. The Company is developing its lead product
candidate, entinostat, a once-weekly, oral, small molecule, class I
HDAC inhibitor, in combination with exemestane and several approved
PD-1/PD-L1 antagonists. The Company's pipeline also includes
SNDX-6352, a monoclonal antibody that blocks the colony stimulating
factor 1 (CSF-1) receptor, as well as a portfolio of potent and
selective inhibitors targeting the binding interaction of Menin
with MLLr. For more information, please
visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax's Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
progress, timing, clinical development and scope of clinical trials
and the reporting of clinical data for Syndax's product candidates,
and the potential use of our product candidates to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical or clinical studies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
SOURCE Syndax Pharmaceuticals